{'text': 'Amgen Presents Phase 3 Data At ASCO Showing Prolia® (Denosumab) Significantly Reduced Bone Fractures In Breast Cancer Patients Receiving Aromatase Inhibitors', 'publisher': {'href': 'https://www.fiercepharma.com', 'title': 'FiercePharma'}, 'created_at': 'Fri, 05 Jun 2015 07:00:00 GMT', 'description': 'Amgen Presents Phase 3 Data At ASCO Showing Prolia® (Denosumab) Significantly Reduced Bone Fractures In Breast Cancer Patients Receiving Aromatase Inhibitors  FiercePharma', 'url': 'https://news.google.com/rss/articles/CBMiywFBVV95cUxOeEtJeTlNdFEwN1ZkRzd4RVp5enhYX3BMbjU3UkR5MTEteHhQMnV5RGJJajFyN2Z3cEN1MmRCRlBmSVVYQk5wbTVaNDlUYVdHc0VVNjEyNzhpdndDT1NySS1sQWNnQ2lmelcxVDRYMlVUcEh1eXB2OUpJUHdlbDhld1lfQlZ3eFM4ejctWHhtMk81WEdWN2VTX2thT1RGRHB4XzhxNW55NEhSNGNIdDJkTS04T3RHMkFjQ3drVXVVaXVaR2duVVh2c0pwYw?oc=5&hl=en-SG&gl=SG&ceid=SG:en'}
